TO EVALUATE THE SAFETY AND EFFICACY FDC OF ROSUVASTATIN CALCIUM 5 mg & FENOFIBRATE 145 mg V/S ROSUVASTATIN 5mg IN PATIENTS SUFFERING WITH MIXED DYSLIPEDEMIA?

INTERVENTION: Intervention1: FDC OF ROSUVASTATIN CALCIUM 5 mg & FENOFIBRATE 145 mg: ROSUVASTATIN CALCIUM 5 mg & FENOFIBRATE 145 mg for 12 weeks Control Intervention1: ROSUVASTATIN: 5mg for 12 weeks CONDITION: PATIENTS SUFFERING WITH MIXED DYSLIPEDEMIA PRIMARY OUTCOME: Change from baseline in low density lipoprotein cholesterol after 12 weeks.‐‐‐‐‐‐Timepoint: 12 weeks SECONDARY OUTCOME: Change from baseline in total cholesterol, triglycerides, high density lipoprotein cholesterol, and lipoprotein subtypes after 12 weeks.; Number of patients who reach target LDL after 12 weeks. ; ‐‐‐‐‐‐Timepoint: 12 weeks INCLUSION CRITERIA: Subjects of either sex of age 18 and 70 years. Low‐density lipoprotein (LDL)‐cholesterol levels > 100 mg/dL, high‐density lipoprotein (HDL)‐cholesterol levels < 50 mg/dL (for women) and < 40 mg/dl (for men), or triglyceride levels > 150 mg/dL. Willing to give written informed consent.